Drug Dosing in Obesity
Pharmacokinetic changes in obesity — increased volume of distribution for lipophilic drugs, altered hepatic metabolism, augmented renal clearance — and practical dosing guidance using total body weight, lean body weight, and adjusted body weight scalars for common clinical scenarios including vancomycin, aminoglycosides, heparins, and bariatric surgery patients.
How obesity alters pharmacokinetics
Obesity — defined as BMI ≥30 kg/m², with extreme obesity ≥40 kg/m² — creates a distinct physiological milieu that alters all four pharmacokinetic processes. Understanding which specific PK parameters are affected, and in which direction, is essential for selecting the appropriate dosing weight scalar and monitoring approach.
Absorption (A)
Elevated intra-abdominal pressure slows gastric emptying. Insulin resistance alters GI motility. For oral drugs, Tmax may be delayed. Subcutaneous injections (insulin, heparin, enoxaparin) may have altered absorption due to increased subcutaneous adipose tissue and reduced skin capillary density. Intramuscular injections may inadvertently be administered into fat rather than muscle, delaying absorption.
Distribution (D)
The most consistently altered parameter. Adipose tissue constitutes 40–50% of total body weight in extreme obesity vs ~20–25% in normal weight. Lipophilic drugs (log P >0) distribute extensively into adipose tissue — Vd increases proportionally with fat mass. Hydrophilic drugs distribute primarily into lean body water — Vd increases proportionally with lean body mass, which increases sub-proportionally with weight.
Metabolism (M)
CYP2E1 activity is increased 2–3 fold (substrate: acetaminophen, ethanol, volatile anaesthetics). CYP3A4 activity may be increased or reduced depending on hepatic steatosis severity. Non-alcoholic fatty liver disease (NAFLD/NASH) progressively impairs glucuronidation (UGT enzymes) and phase I metabolism as it progresses to cirrhosis. Plasma albumin and alpha-1-acid glycoprotein concentrations may be altered, affecting protein binding.
Elimination (E)
GFR and renal tubular secretion are often increased in early/moderate obesity (augmented renal clearance — ARC), leading to faster elimination of renally cleared drugs. This is exacerbated in critically ill obese patients. Advanced obesity-related CKD reduces renal clearance. Cockcroft-Gault using ideal body weight is recommended for drug dosing eGFR estimation to avoid overestimating clearance in obese patients.
Body weight scalars: TBW, IBW, LBW, and ABW
The choice of weight scalar for drug dosing should match the drug's distribution characteristics. No single scalar is universally appropriate:
| Scalar | Formula / definition | When to use | Example drugs |
|---|---|---|---|
| TBW (Total body weight) | Actual measured weight | Lipophilic drugs with high adipose distribution; drugs dosed flat per kg where obesity-specific data supports TBW | Propofol, thiopentone, dexmedetomidine, LMWH (treatment dose), vancomycin load |
| IBW (Ideal body weight) | Devine: M = 50 + 2.3×(Htin−60); F = 45.5 + 2.3×(Htin−60) | Hydrophilic drugs with minimal adipose distribution; initial aminoglycoside loading if ABW not available; digoxin | Digoxin, initial aminoglycoside load, vecuronium (initial dose) |
| LBW (Lean body weight) | James formula: M = 1.1×TBW − 128×(TBW/Htcm)²; F = 1.07×TBW − 148×(TBW/Htcm)² | Pharmacometric models; Bayesian MIPD systems for vancomycin; IV loading doses in PBPK models | Vancomycin (MIPD systems), IV midazolam loading |
| ABW (Adjusted body weight) | IBW + 0.4 × (TBW − IBW) | Drugs with intermediate distribution into adipose tissue; empirically validated | Aminoglycosides (dosing), vancomycin initial dose, some fluoroquinolones, Cockcroft-Gault in some protocols |
The 0.4 correction factor in ABW is empirically derived — it represents the approximate fraction of excess body weight that contributes to aminoglycoside distribution volume. It is not physiologically exact but is clinically validated for initial aminoglycoside dosing. For subsequent doses, therapeutic drug monitoring with MIPD (Bayesian) provides more accurate individualised dosing than weight-scalar calculations alone.
Key drugs requiring special consideration in obesity
Vancomycin
Vancomycin Vd is increased in obesity — obese patients have higher total clearance (CL) and larger Vd, necessitating higher total daily doses (TDD). The 2020 ASHP/SIDP/SCCM consensus guideline recommends AUC/MIC-guided monitoring (target 400–600 mg·h/L) using Bayesian MIPD with TBW-based initial dosing (25–30 mg/kg TBW, maximum 3 g/dose). Bayesian software should be population-parameterised using obese patient PK data. See our TDM guide.
Aminoglycosides
Gentamicin and tobramycin are hydrophilic — use ABW (= IBW + 0.4 × [TBW − IBW]) for initial dose calculation in obesity (empirically validated in the 1970s for gentamicin). Standard extended-interval dosing: 7 mg/kg ABW q24h for gentamicin/tobramycin, 15–20 mg/kg ABW for amikacin. Hartford nomogram monitors subsequent dosing using levels at 6–14 hours post-dose to select q24h/q36h/q48h interval. Augmented renal clearance in young obese patients may require even more frequent monitoring — see our post-antibiotic effect glossary for the PK/PD rationale for extended-interval dosing.
Low-molecular-weight heparins (LMWH)
Enoxaparin for VTE treatment: 1 mg/kg TBW every 12 hours — use TBW without cap (the traditional cap at 144 mg per dose has been removed in most guidelines following evidence that anti-Xa levels are subtherapeutic when TBW is capped). For BMI >50 kg/m², anti-Xa monitoring (target 0.6–1.0 IU/mL at 4 h post-dose for treatment) is recommended. Prophylactic enoxaparin: 40 mg once daily is likely insufficient at BMI >40 kg/m² — 40 mg BD or weight-based dosing (0.5 mg/kg once daily) may be required based on anti-Xa monitoring.
Propofol and IV anaesthetics
Propofol is highly lipophilic (log P = 3.8) with large Vd (~600 L in normal weight, proportionally higher in obesity). Induction dose: use LBW or reduced TBW-based dose to avoid overdose (initial bolus of 1–2 mg/kg LBW). Maintenance infusion: TBW-based rate tends to be used as the large Vd leads to long context-sensitive half-lives. Prolonged propofol infusion in extreme obesity in ICU settings raises propofol infusion syndrome (PRIS) risk — monitor triglycerides, lactate, creatine kinase.
Fluoroquinolones
Ciprofloxacin and levofloxacin are moderately lipophilic — Vd increases with BMI but not as dramatically as with propofol. Standard doses are generally appropriate at BMI 30–40 kg/m². At BMI >40 kg/m², higher standard doses (ciprofloxacin 400 mg IV q8h or 750 mg PO BD; levofloxacin 750 mg q24h) are preferred for serious infections. AUC/MIC-driven dosing — target AUC/MIC >125 for Gram-negative organisms — is the PD goal. See our antibiotic resistance mechanisms guide.
Neuromuscular blocking agents
Succinylcholine: use TBW — pseudocholinesterase activity is increased in obesity proportional to TBW; underdosing with IBW causes inadequate relaxation. Non-depolarising agents (rocuronium, vecuronium): initial dose by IBW to avoid prolonged paralysis (adipose tissue has minimal receptor occupancy); re-dosing guided by train-of-four neuromuscular monitoring.
Bariatric surgery and pharmacokinetics
Bariatric surgery is one of the most common elective surgical procedures globally. The two dominant procedures — Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy — have different mechanisms and different pharmacokinetic consequences.
Roux-en-Y gastric bypass (RYGB)
Creates a small gastric pouch (<30 mL) bypassing the duodenum and proximal jejunum. Pharmacokinetic effects:
- Reduced gastric acid production: smaller pouch with fewer parietal cells → reduced dissolution of pH-dependent drugs (ketoconazole, itraconazole, some statins)
- Bypassed proximal small bowel: drugs absorbed primarily in duodenum/proximal jejunum are substantially reduced (iron, calcium carbonate, some NSAIDs, fat-soluble vitamins)
- Extended-release and enteric-coated formulations: may pass through the pouch without adequate dissolution — require switch to immediate-release equivalents
- First-pass effect: reduced in some patients due to altered hepatic blood flow and potentially reduced gut wall metabolism in the shortened absorptive segment
Sleeve gastrectomy
Removes ~80% of the greater curvature of the stomach, leaving a sleeve-shaped remnant. Gastric emptying is accelerated — faster Tmax, higher Cmax for rapidly absorbed drugs. Does not bypass any intestinal segment, so absorption of duodenally absorbed nutrients and drugs is largely preserved. Extended-release formulations may have altered release profiles due to faster GI transit.
Drugs requiring post-bariatric monitoring
| Drug class / drug | Bariatric issue | Recommendation |
|---|---|---|
| Tacrolimus / cyclosporine | Variable absorption post-RYGB; Cmax altered, AUC unpredictable | Intensive TDM post-surgery; expect dose requirement changes |
| Oral contraceptives | Accelerated gastric emptying may reduce absorption; vomiting post-op | Switch to non-oral routes (patch, ring, IUD, injectable) post-bariatric surgery |
| Lamotrigine | Reduced absorption post-RYGB; lower plasma levels; seizure risk | Monitor levels closely; may need dose increase; switch from ER to IR formulation |
| Levothyroxine | Reduced absorption with bypassed duodenum | Increase monitoring frequency; consider liquid formulation post-RYGB |
| Iron (oral) | Primary absorption site (duodenum) bypassed in RYGB | IV iron infusion preferred for iron-deficiency anaemia post-RYGB |
| Metformin (ER) | ER formulation unreliable post-bariatric surgery | Switch to immediate-release formulation post-RYGB; reassess need (T2DM often resolves) |
Renal dosing in obesity: Cockcroft-Gault and ARC
Estimating GFR for drug dosing in obese patients requires care. CKD-EPI and MDRD are calibrated against measured GFR but were derived in populations without extreme obesity and may underestimate or overestimate GFR depending on the patient.
For drug dosing decisions, Cockcroft-Gault (CG) using IBW remains the most validated approach:
CrCl = [(140 − age) × IBW × (0.85 if female)] / [72 × serum creatinine (mg/dL)]
Using TBW in CG inflates estimated CrCl in obese patients, potentially leading to overdosing of renally cleared drugs (aminoglycosides, vancomycin, direct oral anticoagulants). If IBW < TBW, use IBW; if TBW < IBW (rare), use TBW.
Augmented renal clearance (ARC) — CrCl >130 mL/min — occurs in early/moderate obesity due to hyperfiltration. ARC leads to subtherapeutic drug levels for time-dependent antibiotics dosed conventionally. Young obese patients in ICU commonly have ARC — use 8-hour beta-lactam dosing intervals and TDM-guided vancomycin. See our renal dosing adjustments guide.
FAQ
- How does obesity affect drug pharmacokinetics?
- Obesity increases volume of distribution for lipophilic drugs (proportional to adipose tissue mass), increases CYP2E1 and often CYP3A4 activity, increases GFR and renal clearance in early obesity (augmented renal clearance), and may reduce hepatic phase II metabolism in NAFLD/NASH. No single PK change is universal — each drug requires individual assessment based on its physicochemical properties.
- What is the difference between total body weight, lean body weight, adjusted body weight, and ideal body weight for drug dosing?
- TBW (actual weight) is used for lipophilic drugs. IBW (Devine formula) is used for hydrophilic drugs with minimal adipose distribution. ABW = IBW + 0.4×(TBW − IBW) is empirically validated for aminoglycoside dosing. LBW (James formula) is used in pharmacometric MIPD models. The key: match the weight scalar to the drug's distribution characteristics.
- How does bariatric surgery affect drug absorption and pharmacokinetics?
- RYGB bypasses the duodenum and proximal jejunum — reduces absorption of pH-dependent drugs, iron, calcium carbonate, and drugs primarily absorbed in the proximal GI tract. Extended-release and enteric-coated formulations may fail post-RYGB. Sleeve gastrectomy accelerates gastric emptying (higher Cmax, earlier Tmax) without bypassing absorption sites. Post-bariatric TDM is essential for narrow therapeutic index drugs (tacrolimus, cyclosporine, lamotrigine).
- How should vancomycin be dosed in obese patients?
- Use TBW for loading dose calculation (25–30 mg/kg TBW, capped at 3 g per dose) as vancomycin distributes partly into adipose tissue. AUC/MIC-guided monitoring (target 400–600 mg·h/L) using Bayesian MIPD (DoseMeRx, InsightRx) is recommended per the 2020 ASHP/SIDP/SCCM guideline. MIPD population models should include obese patient PK data for reliable initial Bayesian estimates.